NCT00853021View on ClinicalTrials.gov

Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Kidney Cancer
Interventions
BIOLOGICAL

aldesleukin

SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.

BIOLOGICAL

bevacizumab

Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Jorge A. Garcia, MD

OTHER

NCT00853021 - Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney | Biotech Hunter | Biotech Hunter